Cereno Scientific – The investment case: capital markets day highlights

Rare diseases are finally gaining the regulatory attention they deserve yet patients are still waiting for therapies that change the course of disease, not just manage symptoms. Cereno Scientific aims to be ahead of the curve, as CEO Sten Sörensen puts it, developing novel, potentially disease-modifying treatments for rare cardiopulmonary conditions.

This video captures the key highlights from Cereno Scientific’s 2026 capital markets day, where the company outlined its strategy to target the underlying biology of these diseases. As rare diseases attract increasing focus across biotech, supported by favourable regulatory pathways and strong innovation momentum, Cereno is positioning itself at the intersection of cutting-edge science and high-impact therapeutic opportunity.

At the heart of the approach is epigenetic modulation through HDAC inhibition, aimed at tackling the drivers of vascular remodelling, fibrosis, inflammation and thrombosis. The lead asset, CS1, is being developed for pulmonary arterial hypertension, where current treatments primarily deliver vasodilation rather than disease modification. With compelling Phase IIa data and a Phase IIb trial set to begin soon, Cereno is approaching a key inflection point.

Beyond CS1, Cereno is building a scalable platform with potential across multiple rare cardiopulmonary indications, signalling a bold long-term vision in an increasingly important therapeutic space.